TI
ALT icon

Telemetry Investments’s Altimmune ALT Stock Holding History

Telemetry Investments’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-14,500
Closed -$185K – 145
2022
Q3 		$185K Buy
14,500
+1,500
+12% +$22.1K 0.24% 104
2022
Q2 		$152K Buy
+13,000
New +$80.2K 0.18% 113

Other funds holding ALT

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Telemetry Investments's ALT Position: Q4 2022 in Review

Telemetry Investments sold out of Altimmune (ALT) in Q4 2022, closing a stake of 14,500 shares — an estimated $185K sold.

Telemetry Investments first reported a position in ALT in Q2 2022 and held it in 2 quarters. The position peaked at $185K in Q3 2022. 126 funds tracked by Wall St. Rank hold ALT as of Q4 2022.

  • Telemetry Investments reported no remaining Altimmune position as of Q4 2022 after selling out during the quarter.
  • Telemetry Investments sold 14,500 Altimmune shares in Q4 2022, an estimated $185K.
  • Telemetry Investments first reported a position in Altimmune in Q2 2022 and held it in 2 quarters.
  • Telemetry Investments's Altimmune position peaked at $185K in Q3 2022.
  • 126 funds tracked by Wall St. Rank held Altimmune as of Q4 2022.

Based on Telemetry Investments's 13F filing for Q4 2022, filed 14 Feb 2023.